HEMATOLOGICAL MALIGNANCIES
Clinical trials for HEMATOLOGICAL MALIGNANCIES explained in plain language.
Never miss a new study
Get alerted when new HEMATOLOGICAL MALIGNANCIES trials appear
Sign up with your email to follow new studies for HEMATOLOGICAL MALIGNANCIES, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New immunotherapy combo shows promise for kids with tough cancers
Disease control OngoingThis study tests two immunotherapy drugs, durvalumab and tremelimumab, in children aged up to 17 with advanced solid tumors or certain blood cancers that have not responded to standard treatments. The first part finds the safest dose, and the second part checks if the drugs can s…
Matched conditions: HEMATOLOGICAL MALIGNANCIES
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated May 17, 2026 05:07 UTC
-
New antibody therapy shows promise for Hard-to-Treat blood cancer
Disease control OngoingThis study tests a new drug called talquetamab for people with multiple myeloma that has come back or stopped responding to other treatments. The drug works by helping the immune system attack cancer cells. The main goals are to find a safe dose and check for side effects in abou…
Matched conditions: HEMATOLOGICAL MALIGNANCIES
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated May 17, 2026 05:06 UTC
-
New antibody drug shows promise for Hard-to-Treat blood cancer
Disease control OngoingThis early-stage study tests a new drug, teclistamab, in 302 people with multiple myeloma that has come back or not responded to other treatments. The drug is designed to help the immune system attack cancer cells. The main goals are to find a safe dose and check for side effects…
Matched conditions: HEMATOLOGICAL MALIGNANCIES
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New drug shows promise for Hard-to-Treat blood cancer
Disease control OngoingThis study tests a new drug called teclistamab in people with multiple myeloma that has come back or stopped responding to other treatments. The drug is designed to help the immune system attack cancer cells. About 194 participants will receive the drug to see how well it shrinks…
Matched conditions: HEMATOLOGICAL MALIGNANCIES
Phase: PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated May 11, 2026 20:49 UTC
-
New drug target for hard-to-treat blood cancers enters early human testing
Disease control OngoingThis study tests an experimental drug called AZD9829 in 56 adults with blood cancers that have a specific marker (CD123) and have not responded to other treatments. The main goals are to find a safe dose and to check for side effects. The drug is given through a vein, either alon…
Matched conditions: HEMATOLOGICAL MALIGNANCIES
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 26, 2026 19:35 UTC
-
Simple breathing trick may ease chemo side effects
Symptom relief OngoingThis study looked at whether relaxation breathing exercises can help manage nausea and vomiting caused by chemotherapy in people with blood cancers. Sixty-eight adults took part; half did breathing exercises three times a day plus standard care, while the other half received only…
Matched conditions: HEMATOLOGICAL MALIGNANCIES
Phase: NA • Sponsor: Marmara University • Aim: Symptom relief
Last updated May 17, 2026 05:26 UTC
-
Can a heavier blanket help blood cancer patients get better sleep?
Symptom relief OngoingThis study looks at whether weighted blankets can improve sleep quality in people with blood cancers. Twenty adult outpatients at MD Anderson Cancer Center will try the blankets, and researchers will track any side effects and changes in sleep. The goal is to see if this simple, …
Matched conditions: HEMATOLOGICAL MALIGNANCIES
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated May 04, 2026 16:21 UTC
-
CAR-T Patients' immune recovery and vaccine response under study
Knowledge-focused TerminatedThis study was designed to track how the immune system recovers after CAR-T cell therapy and whether a pneumonia vaccine (PCV-21) given six months later can work. It planned to enroll 50 adults with blood cancers or solid tumors. However, the study was withdrawn before any partic…
Matched conditions: HEMATOLOGICAL MALIGNANCIES
Phase: PHASE1, PHASE2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated May 17, 2026 05:05 UTC